Form 8-K Bioventus Inc. For: May 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bioventus reiterates 2026 guidance after FDA device reclassification
May 21, 2026 5:14 PM EDTBioventus Inc. (NASDAQ: BVS) said it expects to maintain its 2026 financial guidance following regulatory changes affecting its bone healing device.
The U.S. Food and Drug Administration issued a final order on April 16, 2026, reclassifying non-invasive bone growth stimulators from Class III to Class II devices.... More
